Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 90430-14-1 | MDL No. : | MFCD02258769 |
Formula : | C7H10BrNO | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | ZJKNRZBDZNVNRX-UHFFFAOYSA-N |
M.W : | 204.06 g/mol | Pubchem ID : | 2759293 |
Synonyms : |
|
Num. heavy atoms : | 10 |
Num. arom. heavy atoms : | 6 |
Fraction Csp3 : | 0.14 |
Num. rotatable bonds : | 1 |
Num. H-bond acceptors : | 2.0 |
Num. H-bond donors : | 2.0 |
Molar Refractivity : | 46.18 |
TPSA : | 46.25 Ų |
GI absorption : | High |
BBB permeant : | Yes |
P-gp substrate : | No |
CYP1A2 inhibitor : | No |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | Yes |
Log Kp (skin permeation) : | -6.86 cm/s |
Log Po/w (iLOGP) : | 0.0 |
Log Po/w (XLOGP3) : | 0.96 |
Log Po/w (WLOGP) : | 1.66 |
Log Po/w (MLOGP) : | 1.37 |
Log Po/w (SILICOS-IT) : | 0.98 |
Consensus Log Po/w : | 0.99 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 0.0 |
Bioavailability Score : | 0.55 |
Log S (ESOL) : | -2.09 |
Solubility : | 1.67 mg/ml ; 0.00817 mol/l |
Class : | Soluble |
Log S (Ali) : | -1.52 |
Solubility : | 6.18 mg/ml ; 0.0303 mol/l |
Class : | Very soluble |
Log S (SILICOS-IT) : | -1.82 |
Solubility : | 3.07 mg/ml ; 0.0151 mol/l |
Class : | Soluble |
PAINS : | 0.0 alert |
Brenk : | 0.0 alert |
Leadlikeness : | 1.0 |
Synthetic accessibility : | 1.0 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P261-P301+P312-P302+P352-P304+P340-P305+P351+P338 | UN#: | N/A |
Hazard Statements: | H302-H315-H319-H335 | Packing Group: | N/A |
GHS Pictogram: |
![]() |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
93% | With sodium hydrogencarbonate In methanol at 20℃; for 24h; | |
87% | With sodium hydrogencarbonate In methanol at 20℃; for 20h; | |
86% | With sodium hydrogencarbonate In methanol at 20℃; for 20h; Inert atmosphere; |
86% | With sodium hydrogencarbonate In methanol at 20℃; for 20h; | |
In 1,4-dioxane; water at 20℃; for 4h; | 30.A A solution of 4.3 g (21 mmol) of 4-hydroxybenzylamine hydrobromide and 5.49 g (65 mmol) NaHCO3 in 17 ml dioxane and 4 ml of water was treated with 5.06 g (23 mmol) di-tert-butyl dicarbonate and stirred for 4 h at room temperature. The organic phase was extracted with water/dichloromethane (two times), dried (MgSO4), and evaporated to give 4.75 g of the title compound as a colorless oil. MS: 223.1 (M+). | |
With sodium hydrogencarbonate In methanol at 20℃; | 8.a.a fert-Butyl 4-hvdroxybenzylcarbamate[0169] 4-(Aminomethyl)phenol hydrobromide (0.36 g, 1.75 mmol) was dissolved in20 mL MeOH. Boc-anhydride (0.45 g, 2.08 mmol) and NaHCO3 (0.45 g, 5.36 mmol) were added. The mixture was stirred at room temperature over night. The reaction was quenched with water and the product was extracted with CH2Cl2. The combined organic phases were dried (Na2SO4), filtered and concentrated to give 0.48 g of crude product: 1H NMR (400-67-SDI-10975vl Attorney Docket No. 12560-046-228MHz, CDCh) δ 7.15 (d, J= 8.2, 2H), 6.85 - 6.71 (m, 2H), 4.99 (s, IH), 4.76 (s, IH), 4.23 (d, J= 5.5, 2H), 1.48 (s, 9H). | |
1.79 g | With sodium hydroxide In tetrahydrofuran; water at 20℃; for 18h; |